UPDATED: May 24, 2021 13:51 IST
The drug will be available through leading hospitals and Covid treatment centers. (Photo: PTI/ for Representation)
Drug majors Roche India and Cipla on Monday announced launch of Roche s Antibody Cocktail in India priced at Rs 59,750 per dose for the treatment of mild to moderate Covid-19 in patients who are at high risk. The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients, Cipla and Roche said in a joint statement.